TORRENT PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,690 INR | -0.07% |
|
+6.05% | +16.72% |
| Sales 2024 * | 108B 1.3B 1.77B | Sales 2025 * | 122B 1.46B 2B | Capitalization | 911B 10.92B 14.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 16.43B 197M 269M | Net income 2025 * | 20.55B 247M 337M | EV / Sales 2024 * | 8.76 x |
| Net Debt 2024 * | 37.16B 446M 609M | Net Debt 2025 * | 25.26B 303M 414M | EV / Sales 2025 * | 7.67 x |
| P/E ratio 2024 * |
56.1
x | P/E ratio 2025 * |
44.3
x | Employees | 13,247 |
| Yield 2024 * |
0.8% | Yield 2025 * |
0.9% | Free-Float | 28.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Torrent Pharmaceuticals Limited
More recommendations
More press releases
| 1 day | -0.07% | ||
| 1 week | +6.05% | ||
| Current month | +3.43% | ||
| 1 month | +4.93% | ||
| 3 months | +8.74% | ||
| 6 months | +39.96% | ||
| Current year | +16.72% |
1 week
2 537.15
2 730.40
1 month
2 508.652 730.40
Current year
2 270.152 745.55
1 year
1 599.002 745.55
3 years
1 238.832 745.55
5 years
726.502 745.55
10 years
280.002 745.55
| Managers | Title | Age | Since |
|---|---|---|---|
Sudhir Menon
DFI | Director of Finance/CFO | - | - |
| Compliance Officer | - | 22-07-31 | |
Jinesh Shah
COO | Chief Operating Officer | 47 | 19-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 82-06-22 | |
| Chairman | 60 | 85-12-31 | |
Nayantara Bali
BRD | Director/Board Member | 57 | 19-03-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.28% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2,690 | -0.07% | 4,270 |
| 24-04-25 | 2,692 | +0.28% | 1,149 |
| 24-04-24 | 2,685 | +1.85% | 4,480 |
| 24-04-23 | 2,636 | +1.76% | 1,466 |
| 24-04-22 | 2,591 | +2.12% | 4,372 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am
More quotes
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
2,690
INR
Average target price
2,729
INR
Spread / Average Target
+1.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.72% | 10.92B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- TORNTPHARM Stock
